Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Garfield Heights, Ohio Clinical Trials

A listing of Garfield Heights, Ohio clinical trials actively recruiting patient volunteers.

RESULTS

Found (34) clinical trials

PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers

Protocol PEN-221-001 will first enroll patients into a dose escalation phase, where a Bayesian logistic regression model, guided by the escalation with overdose control principle and overseen by a safety review committee, will be used to make dose recommendations and estimate the maximum tolerated dose (MTD). Once the MTD has ...

Phase

6.32 miles

Learn More »

Neoadjuvant Pembrolizumab in Combination With Gemcitabine Therapy in Cis-eligible/Ineligible UC Subjects

OUTLINE: This is a multi-center study. INVESTIGATIONAL TREATMENT: Phase Ib Dose-Finding Cohort I Cisplatin-Eligible: Phase Ib is a 3+3 design for the cisplatin-eligible group only. Cisplatin-eligible subjects receive: gemcitabine 1000mg/m2 IV D1 and D8 every 21 days repeated for 4 cycles; cisplatin 70mg/m2 IV D1 and D8 every 21 days, ...

Phase

6.32 miles

Learn More »

A Study to Evaluate the Safety and Effectiveness of ILIxadencel Administered Into Tumors in Combination With Checkpoint Inhibitor (CPI) in Patients With ADvanced Cancer

Despite improvements achieved with the use of CPIs, 50-80% of cancer patients do not respond to this therapy. There is growing evidence that combining CPIs with other forms of immunotherapy has the potential to improve the desired effects of both CPIs and immunotherapies. This study looks at the safety and ...

Phase

6.32 miles

Learn More »

Laser Interstitial Thermotherapy (LITT) Combined With Checkpoint Inhibitor for Recurrent GBM (RGBM)

Primary Objectives: Phase I: To determine the optimal timing for combining LITT and pembrolizumab in patients with rGBM: To determine the feasibility, safety, tolerability and side effect profiles for combining LITT and pembrolizumab at various time points pre-LITT vs. post-LITT (Phase I). 2. Phase II: To estimate the response to ...

Phase

6.32 miles

Learn More »

Hematopoietic Stem Cell Transplant for Sickle Cell Disease

Primary Objective To evaluate the safety and feasibility of hematopoietic stem cell transplant (HSCT) after treatment with fludarabine in adult patients with Sickle Cell Disease (SCD). Secondary Objective(s), in HSCT for SCD To evaluate the rates of disease-free and overall survival in both MSD and alternate graft donor (MUD, haploidentical, ...

Phase

6.32 miles

Learn More »

CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer

Phase I Primary Objective: To determine the safety, tolerability and recommended phase II dose (RP2D) of combination CB-839 and capecitabine chemotherapy in patients with advanced solid tumors for whom there are no remaining treatment options or for whom single agent capecitabine is an acceptable therapy. Phase II Primary Objective: To ...

Phase

6.32 miles

Learn More »

Vision Restoration With a Collagen Crosslinked Boston Keratoprosthesis Unit

The study is a multi-center, parallel, randomized, double-blinded study with subsequent follow-up period of two years. Eight-four subjects across twelve sites will be randomized 1:1 to receive either a corneal tissue that have been cross-linked or not cross-linked (No UVA light source). Cross-linking is a term that refers to the ...

Phase

6.32 miles

Learn More »

Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML)

This is a multi-center, open-label, dose escalation study that will determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of liposomal annamycin as a single agent for the treatment of subjects with AML that is refractory to or relapsed after standard induction therapy

Phase

6.32 miles

Learn More »

Study to Evaluate the Safety & Tolerability of MRT5005 Administered by Nebulization in Adults With Cystic Fibrosis

This Phase 1/2, first-in-human study will evaluate the safety and tolerability of single and multiple escalating doses of MRT5005 administered by nebulization to the respiratory tract of adult subjects with CF. This study will also assess the delivery of the drug to bronchial epithelial cells following multiple doses of MRT5005, ...

Phase

6.32 miles

Learn More »

A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Patients With Advanced Solid Tumors

This study will evaluate the safety profile, tolerability, PK, PD, and preliminary efficacy of BMS-813160 alone or in combination with either chemotherapy or nivolumab in participants with metastatic colorectal and pancreatic cancers.

Phase

6.37 miles

Learn More »